These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children. Kanesaki T, Baba K, Tsuda N, Yabuuchi H, Yamanishi K, Takahashi M. Biken J; 1986 Dec; 29(3-4):63-71. PubMed ID: 3304276 [Abstract] [Full Text] [Related]
10. Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age. Yadav S, Thukral R, Chakarvarti A. Indian J Med Res; 2003 Nov; 118():183-6. PubMed ID: 14723482 [Abstract] [Full Text] [Related]
12. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis. Flynn JT, Frisch K, Kershaw DB, Sedman AB, Bunchman TE. Adv Perit Dial; 1999 Nov; 15():269-72. PubMed ID: 10682116 [Abstract] [Full Text] [Related]
13. Evaluation of mumps antibodies after measles-mumps-rubella (MMR) vaccines. Ozaki K, Kuno-Sakai H, Kimura M. Tokai J Exp Clin Med; 1987 Dec; 12(5-6):305-11. PubMed ID: 3508655 [Abstract] [Full Text] [Related]
14. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. King SM, Saunders EF, Petric M, Gold R. Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367 [Abstract] [Full Text] [Related]
15. Immune response to Edmonston-Zagreb measles virus strain in monovalent and combined MMR vaccine. Beck M, Smerdel S, Dedić I, Delimar N, Rajninger-Miholic M, Juzbasić M, Manhalter T, Vlatković R, Borcić B, Mihajić Z. Dev Biol Stand; 1986 Apr; 65():95-100. PubMed ID: 3556780 [Abstract] [Full Text] [Related]
16. Measles, mumps, rubella antibody surveillance: pilot study in Grampian, Scotland. Narayan KM, Moffat MA. Health Bull (Edinb); 1992 Jan; 50(1):47-53. PubMed ID: 1612895 [Abstract] [Full Text] [Related]
17. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Johnson CE, Kumar ML, Whitwell JK, Staehle BO, Rome LP, Dinakar C, Hurni W, Nalin DR. Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673 [Abstract] [Full Text] [Related]
18. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children. Dhiman N, Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz VS, Jacobsen SJ, Poland GA. Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638 [Abstract] [Full Text] [Related]
19. Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response. Halperin SA, McGrath P, Smith B, Houston T. J Pediatr; 2000 Jun; 136(6):789-94. PubMed ID: 10839878 [Abstract] [Full Text] [Related]
20. [Clinico-immunologic evaluation of a trivalent vaccine against measles, rubella and mumps]. Schettini F, Manzionna MM, De Mattia D, Amendola F, Di Bitonto G. Minerva Pediatr; 1989 Mar; 41(3):117-22. PubMed ID: 2747598 [Abstract] [Full Text] [Related] Page: [Next] [New Search]